| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.88M | 91.89M | 84.37M | 88.19M | 143.87M | 189.38M |
| Gross Profit | 2.59M | 6.49M | 21.22M | 38.49M | 65.27M | 94.99M |
| EBITDA | -17.33M | -28.31M | -36.05M | -30.94M | -35.40M | -21.93M |
| Net Income | -24.20M | -35.85M | -49.32M | -43.21M | -44.35M | -21.13M |
Balance Sheet | ||||||
| Total Assets | 173.84M | 137.47M | 165.74M | 193.80M | 190.72M | 246.34M |
| Cash, Cash Equivalents and Short-Term Investments | 45.94M | 2.30M | 33.95M | 11.36M | 32.35M | 48.18M |
| Total Debt | 50.86M | 60.74M | 71.40M | 79.92M | 32.92M | 36.65M |
| Total Liabilities | 85.91M | 95.08M | 107.53M | 113.90M | 66.58M | 73.39M |
| Stockholders Equity | 86.62M | 42.06M | 58.21M | 80.36M | 124.27M | 168.75M |
Cash Flow | ||||||
| Free Cash Flow | -3.68M | -35.37M | 13.80M | -76.70M | -13.24M | -23.02M |
| Operating Cash Flow | -3.61M | -35.21M | 14.42M | -75.93M | -11.02M | -19.19M |
| Investing Cash Flow | -18.00K | -101.00K | -2.00K | 15.03M | 6.67M | -8.57M |
| Financing Cash Flow | 3.07M | 3.63M | 8.13M | 39.30M | -10.74M | -9.10M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$398.00M | 15.19 | 18.10% | 6.94% | 10.65% | 25.96% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
52 Neutral | HK$91.31M | 5.41 | 20.69% | 8.93% | -13.44% | ― | |
51 Neutral | HK$287.00M | -12.73 | -4.25% | 9.76% | 8.85% | -18.82% | |
44 Neutral | HK$165.95M | -2.42 | -39.50% | ― | -32.54% | 71.35% | |
44 Neutral | HK$189.84M | -2.23 | -11.32% | 31.48% | 4.60% | -9.42% | |
41 Neutral | HK$76.58M | -0.04 | ― | ― | -72.73% | -764.81% |
AI Health Technology Limited has announced board changes effective 12 January 2026, including the resignation of independent non-executive director Li Wei, who is stepping down from the board and the audit committee to focus on other business commitments. The company has moved to maintain independent oversight by re-designating existing non-executive director Zhang Yuanjie as an independent non-executive director, citing her lack of involvement in daily operations, absence of financial interests in the group, and compliance with Hong Kong listing independence criteria. Zhang, a seasoned corporate consultant with over 20 years of experience in investment, M&A and restructuring across the Asia-Pacific region, has signed a new one-year service contract with annual remuneration of HK$120,000 and will be subject to shareholder re-election, signaling the company’s effort to preserve governance continuity and independent judgment on the board following Li’s departure.
The most recent analyst rating on (HK:1715) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Miji International Holdings Limited stock, see the HK:1715 Stock Forecast page.
AI Health Technology Limited has announced the effective date of its capital reduction and share sub-division, which took effect on December 1, 2025. This strategic move is expected to optimize the company’s capital structure and potentially enhance shareholder value. Shareholders are invited to exchange their existing share certificates for new ones at no cost during the specified period, although the old certificates will remain valid as proof of ownership.
The most recent analyst rating on (HK:1715) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Miji International Holdings Limited stock, see the HK:1715 Stock Forecast page.